Current blood cancer care, case by case.
Hematologic Oncology Update brings medical oncologists into detailed conversations about hematologic cancer care. Recent episodes track multiple myeloma, lymphoma, leukemia, and immune thrombocytopenia through clinical trials, ASH data, drug mechanisms, toxicity management, and cases.
PRESS PLAY
Hematologic Oncology Update is a highly technical medical series for clinicians following hematologic cancer care. Its center of gravity is the expert interview. The show favors trial data, treatment mechanisms, case discussion, and practical interpretation over general health explanation. Recent episodes spend significant time on relapsed and refractory multiple myeloma. CELMoDs receive close attention, including iberdomide, mezigdomide, dosing schedules, dose optimization, extramedullary disease, and Phase III trial design. The myeloma coverage also follows CAR-T, in vivo CAR approaches, BCMA-targeted therapy, bispecifics, belantamab mafodotin, and sequencing around more intensive immunotherapies. Immune thrombocytopenia episodes are case-driven and clinically specific. They cover acute thrombocytopenia, platelet counts, steroid response, IVIG, rituximab, fostamatinib, TPO-RAs, BTK inhibitors, BAF-R antagonists, and immune checkpoint inhibitor-associated ITP. The show repeatedly asks what new evidence means for the patient in front of the oncologist. That gives the conversations a grounded feel even when the science is complex. ASH 2025 reviews supply much of the recent frame, with faculty weighing meeting abstracts, emerging agents, and unapproved regimens. The acute lymphoblastic leukemia coverage looks at CD19 x CD3 bispecific T-cell engaging antibodies and the evolving role of blinatumomab. Lymphoma episodes bring bispecific antibodies into aggressive lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. The language is dense. The value is precision. Hematologic Oncology Update is best for listeners already comfortable with oncology shorthand, disease subtypes, trial endpoints, and adverse-event management. It offers a window into how physicians connect new data with patient selection, toxicity, access, and next-line therapy. The result is not a broad explainer, but a working-room view of hematologic oncology as it changes in real time.
Made for: For medical oncologists, hematologists, oncology trainees, and clinically fluent listeners tracking blood cancer treatment. It assumes comfort with trial language, drug classes, endpoints, and case-based decision-making.
What sets it apart: The show pairs specialist interviews with cases, so research updates are constantly tested against practical treatment decisions. Its strength is the granular movement from ASH data to dosing, eligibility, toxicity, and sequencing.
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
A platelet count of five leads to flightless birds; your clinical curiosity has found its people.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A focused review of how cell-mod trial design shapes decisions on dose, eligibility, and delaying CAR-T.
The episode tracks Dr. Paul Richardson from the Phase III Excalibur RRMM trial in relapsed refractory disease into the practical question that follows if two cell mod studies read out positively: how clinicians might choose between them.
A practical ASH case review on difficult ITP decisions, early treatment failure, and restarting immunotherapy.
Immune thrombocytopenia is treated here as a real-world management problem, not a tidy algorithm. In this final ASH 2025 installment, Dr. Hany Alsamkari works through cases from community-based oncologists, including a young patient whose platelet count rises from 4,000 to…
A focused review of cell-mod biology, key studies, and extramedullary disease in multiple myeloma.
Cell-mod drugs anchor this PlayNext episode on where oral agents may fit next in multiple myeloma care. Dr. Paul Richardson lays out how they differ from immunomodulators, how they work through the Cereblon E3 ligase complex, and why they may matter when resistance limits other…
A case-led ITP update that uses platelet biology to sharpen thinking about bleeding risk, relapse, and emerging treatment choices.
Immune thrombocytopenia receives a case-based What Happened at ASH 2025 review that keeps new treatment ideas anchored to the bedside question: what does a very low platelet count really say about bleeding risk? Dr. Neil Love and Dr.
A focused ALL review on how CD19-directed antibodies could move from salvage therapy toward earlier, lower-burden care.
CD19-CD3 bispecific T-cell engagers make for a revealing ALL episode, with Blenitumumab's 2014 FDA approval serving as the anchor for a field that is only now seeing possible contenders and new delivery ideas come into view. Dr. Neil Love's conversation with Dr.
Morning medical evidence, compressed for practice.
Medical research, translated through patient experience.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
A review of bispecific antibodies for lymphoma presented at ASH 2025, featuring expert faculty discussing key data and clinical implications.
A panel of experts discuss relapsed/refractory multiple myeloma management and key presentations from the ASH 2025 meeting.
Dr.
Dr.